Quantcast
Last updated on April 20, 2014 at 19:30 EDT

Latest Jarvik Stories

2013-12-05 16:24:33

NEW YORK, Dec. 5, 2013 /PRNewswire/ -- JARVIK HEART, Inc., a privately-held company that develops and manufactures cardiac assist devices, announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has granted approval to the Shonin (or pre-market approval) application submitted by Century Medical, Inc., (CMI) for the Jarvik 2000 Heart, a small Left Ventricular Assist Device (LVAD) implanted inside the natural heart. CMI is the exclusive distributor of the Jarvik...

2013-05-02 08:36:30

TEL AVIV, Israel, May 2, 2013 /PRNewswire/ -- Leviticus Cardio [http://www.leviticus-cardio.com ], a portfolio company of the Mofet Venture Accelerator [http://www.mofet-venture.com ], owned by the Trendlines Group, recently performed a successful animal surgical trial using its wireless coplanar energy transfer system (CET) for ventricular assist devices (VAD). The surgery was performed at Assaf Harofeh Hospital and produced a 75% full system efficiency rate as compared with...

2012-08-14 02:29:59

NEW YORK, Aug. 14, 2012 /PRNewswire/ -- JARVIK HEART, Inc., a privately-held company that develops and manufactures cardiac assist devices, announced full FDA approval of its Pivotal Trial for evaluation of the Jarvik 2000® heart for destination therapy (DT) named RELIVE (Randomized Evaluation of Long-term Intraventricular VAD Effectiveness). (Photo: http://photos.prnewswire.com/prnh/20120227/NY60355 ) Use of the device for DT means that it will provide long-term, permanent support to...

2012-02-27 14:28:00

NEW YORK, Feb. 27, 2012 /PRNewswire/ -- JARVIK HEART, Inc., a privately-held company that develops and manufactures cardiac assist devices, announced conditional FDA approval of its Pivotal Trial for evaluation of the Jarvik 2000® heart for destination therapy (DT). Use of the device for DT means that it will provide long-term, permanent support to end-stage congestive heart failure patients who are not candidates for heart transplant. The approval permits fifty medical centers to...

2011-12-02 23:01:00

WASHINGTON, Dec. 3, 2011 /PRNewswire-USNewswire/ -- Following is the daily "Profile America" feature from the U.S. Census Bureau: (Logo: http://photos.prnewswire.com/prnh/20110428/DC91889LOGO) SATURDAY, DECEMBER 3: REPLACING DAMAGED HEARTS Profile America -- Saturday, December 3rd. Two pioneering efforts to save the lives of patients with terminal heart problems occurred this month in the past. On this date in 1967, the first successful heart transplant was performed by Dr. Christian...

c8057c7af279fe3c9b03e633d1aa11a7
2008-09-03 08:30:00

Six months after Lipitor ads were yanked off TV amid complaints of misleading advertising, parent company Pfizer Inc. (PFE) has put the world's top-selling cholesterol fighter back in the spotlight. Last time around Pfizer used a celebrity doctor endorser who's never practiced medicine. But this time, Pfizer is leaving out the celebrity. In the new television ads, the spokesman is a talent agent from the San Francisco Bay area who tells viewers he started taking Pfizer's Lipitor after...

2008-08-09 03:00:09

By Anonymous DR. ROBERT JARVIK doesn't row. The spokesperson for Pfizer's cholesterol-lowering medication Lipitor also isn't a cardiologist, nor is he licensed to practice medicine. And former colleagues even contest his claim to be the "inventor of the Jarvik artificial heart." After a Congressional committee began looking into the misrepresentation of Jarvik's credentials, Pfizer pulled long- running Lipitor commercials featuring Jarvik off the air in February. Pfizer spent more than $258...